Skip to main content
. 2017 May 1;214(5):1547–1555. doi: 10.1084/jem.20161451

Figure 2.

Figure 2.

Quantification of plasma, serum, and CSF IFNα in patient cohorts. (A) Plasma from healthy controls (n = 20) and patients with RVCL (n = 30), SLE (n = 72), JDM (n = 43), and molecularly defined interferonopathies (n = 27) were assayed by Simoa for IFNα protein. Values were assessed by one-way ANOVA test (Kruskal–Wallis) and Dunn’s multiple comparison testing between groups. (B) CSF samples from acute meningitis (n = 9), acute encephalitis (n = 9), acute meningoencephalitis (n = 1), and RVCL (n = 12) were assayed by Simoa for IFNα protein. Values were assessed by Mann–Whitney T test. ***, P < 0.001; ****, P < 0.0001; n.s., not significant; horizontal lines indicate the median.